Insider trade

Baxter International (BAX): Director received 13K shares

Jeffrey A Craig, Director at Baxter International, reported a grant / award of 13K shares.

13K
Shares
Traded
May 5, 2026
Filed
May 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 16, 2026, Baxter International Inc. (the “Company”) announced that, as of such date (the “Transition Date”), Joel Grade’s service as Executive Vice President and Chief Financial Officer (“CFO”) of the Company has ceased and, as of such date, Mr. Grade has transitioned into a non-executive officer role and will continue employment with the Company in an advisory capacity through April 30, 2026.”
  2. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  3. Apr 21, 20265% stakePZENA INVESTMENT MANAGEMENT LLC reported a passive stake (13G) of 12.7%
  4. Apr 27, 20265% stakeBlackRock, Inc. reported a passive stake (13G) of 6.4%
  5. Apr 29, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  6. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.4%
  7. May 4, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On May 4, 2026, the Compensation and Human Capital Committee of the Board of Directors (the “Board”) of Baxter International Inc. (the “Company”) approved the Baxter International Inc. Executive Severance and Change in Control Plan (the “Severance Plan”), effective as of May 4, 2026 (the “Effective Date”).”

What came next

  1. May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 9.0%
  2. Jun 5, 20265% stakeFMR LLC reported a passive stake (13G) of 10.3%
  3. Jul 29, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  4. Jul 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 31, 2026, Anita Zielinski notified Baxter International Inc. (the “Company”) of her decision to resign as the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, effective as of September 15, 2026, to join another company.”
  5. Aug 6, 2026FDAFDA drug approval: Levetiracetam
  6. Aug 6, 2026FDARecall: Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporatio…
  7. Aug 6, 2026FDARecall: Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare C…
  8. Aug 6, 2026FDARecall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter…
  9. Aug 6, 2026FDARecall: Famotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Single Dose Container, Rx Only, Sterile Nonpyrogenic, Baxter International Inc., Baxt…
  10. Aug 6, 2026FDARecall: Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL), 1,000 mg total, in 1000 mL Single Dose Container, Rx only, Sterile Nonpyrogenic,…
  11. Aug 11, 2026FDARecall: Baxter Novum IQ Syringe Pump, Model Number 40800BAXUS
  12. Aug 11, 2026FDARecall: Baxter Novum IQ Syringe Pump, Loaner, Model Number 40800BAXUSL
  13. Aug 13, 2026FDAFDA device clearance: Dashboard (P007000)
  14. Aug 14, 2026FDAFDA drug approval: Sodium Bicarbonate
  15. Aug 17, 2026FDARecall: 0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 units per case. Baxter Healthcare Corporation, Deerfield, IL, 60015, USA, Made i…
  16. Aug 17, 2026FDARecall: Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporation Deerfield, IL, 60016, Made in USA, NDC 00338-0719-06
  17. Aug 18, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  18. Aug 18, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 18, 2026, Baxter International Inc. (the “Company”) appointed John Rogers as Executive Vice President and Chief Financial Officer (“CFO”), effective as of October 1, 2026 (the “Transition Date”).”
  19. Aug 18, 2026FDARecall: PRO+ 40" MRS SURFACE, mattress with Advanced Microclimate Technology (AMT) uses a non-powered system of intake and output valves to provide weight-based pressu…
  20. Aug 18, 2026FDARecall: PRO+ MRS SURFACE FOR VERSACARE, mattress with Advanced Microclimate Technology (AMT) uses a non-powered system of intake and output valves to provide weight-ba…
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Baxter International

For Baxter International, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BAX page.

Other recent filings by Jeffrey A Craig, Director

The full history of Jeffrey A Craig, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Baxter International (BAX) insider traded, and how much?

Jeffrey A Craig, Director at Baxter International, reported a grant / award of 13K shares. Not an open-market trade.

When did it happen, and when was it made public?

Traded: May 5, 2026. Filed: May 7, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Baxter International recently?

For Baxter International, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the BAX page.

Does this mean BAX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Baxter International

Everything OQRO holds on this company is on its BAX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data